Golden Biotechnology Corp. (TPEx: 4132), a leading Taiwanese biopharmaceutical company, announced that it received the notice from assigned CRO that US FDA had replied with the Acknowledgement of Receipt of its submission of Pre-EUA Meeting Request for COVID-19 clinical new drug Antroquinonol. (Application Type/Number: IND149841, eCTD Sequence Number: 0025).

This Pre-EUA Meeting Request is for the application of the new drug Antroquinonol which completed the clinical trial (IND149841) targeting to hospitalized patients with mild to moderate Covid-19 pneumonia.